Insider Selling: Bioventus Inc. (NYSE:BVS) CFO Sells $19,000.00 in Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 4,000 shares of the firm’s stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $4.75, for a total transaction of $19,000.00. Following the completion of the transaction, the chief financial officer now directly owns 34,665 shares of the company’s stock, valued at $164,658.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Mark Leonard Singleton also recently made the following trade(s):

• On Friday, March 22nd, Mark Leonard Singleton sold 5,541 shares of Bioventus stock. The shares were sold at an average price of $5.39, for a total transaction of $29,865.99.

Bioventus Trading Up 1.3 %

BVS stock opened at $4.70 on Thursday. The firm has a fifty day moving average price of $4.96 and a 200 day moving average price of $4.48. Bioventus Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $6.08. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.01 and a current ratio of 1.53. The firm has a market cap of $372.08 million, a PE ratio of -1.87 and a beta of 0.50.

Bioventus (NYSE:BVS) last issued its quarterly earnings results on Tuesday, March 12th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. The company had revenue of $135.42 million during the quarter, compared to the consensus estimate of $124.84 million. Bioventus had a positive return on equity of 2.25% and a negative net margin of 30.49%. Sell-side analysts anticipate that Bioventus Inc. will post 0.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum raised their target price on shares of Bioventus from $6.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, March 13th.

Institutional Trading of Bioventus

A number of institutional investors have recently bought and sold shares of the stock. Juniper Investment Company LLC lifted its position in Bioventus by 2.7% in the third quarter. Juniper Investment Company LLC now owns 6,833,857 shares of the company’s stock worth $22,552,000 after buying an additional 176,870 shares during the last quarter. BlackRock Inc. lifted its position in Bioventus by 7.6% in the third quarter. BlackRock Inc. now owns 2,151,320 shares of the company’s stock worth $15,059,000 after buying an additional 151,471 shares during the last quarter. Vanguard Group Inc. lifted its position in Bioventus by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 1,218,500 shares of the company’s stock worth $6,421,000 after buying an additional 17,420 shares during the last quarter. Kent Lake Capital LLC lifted its position in Bioventus by 15.0% in the third quarter. Kent Lake Capital LLC now owns 1,035,168 shares of the company’s stock worth $3,416,000 after buying an additional 135,168 shares during the last quarter. Finally, First Light Asset Management LLC bought a new stake in Bioventus in the first quarter worth $12,712,000. 62.94% of the stock is currently owned by institutional investors.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.